Under the Pa

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# **TRANSMITTAL FORM**


(to be used for all correspondence after initial filing)

Application (4dinber	10/806,515
Filing Date	March 22, 2004
First Named Inventor	Tom F. LUE
Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	220022001610

Total Number of Pages in This Submiss	sion 18	220022001610			
ENCLOSURES (Check all that apply)					
Fee Transmittal Form	Drawing(s)	After Allowance Communication to Group			
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendment/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final	Petition to Convert to a Provisional Application	Proprietary Information			
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter			
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please identify below):			
Express Abandonment Request	Request for Refund	Form PTO-1449, 7 pgs + duplicate 1 Reference Return Postcard			
X Information Disclosure Statement, 3 pages	CD, Number of CD(s)				
Certified Copy of Priority Document(s)					
Response to Missing Parts/ Incomplete Application	Remarks				
Response to Missing Parts	CUSTOMER NO. 25225				
under 37 CFR 1.52 or 1.53		,			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm MORRISON & FOERSTER LLP Laurie L. Hill - 51,804					
Signature Auni All					
Date Jung 30, 2004					

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7-04-04 Signature: (Rhea Amid)





#### CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on July 1, 2004.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Tom F. LUE et al.

Serial No.:

10/806,515

Filing Date:

March 22, 2004

METHODS AND COMPOSITIONS FOR For: PREVENTING AND TREATING MALE ERECTILE DYSFUNCTION AND FEMALE

SEXUAL AROUSAL DISORDER

Examiner: Not Yet Assigned

Group Art Unit: 1646

## INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. A copy of document 128 is submitted herewith. Copies of all other documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/909,544, filed July 19, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

	This Inf	ormation Disclosure Statement is submitted:
	With t	the application; accordingly, no fee or separate requirements are required.
	Before	e the mailing of a first Office Action after the filing of a Request for Continued
	Exami	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. §
	1.97(e	e)(1) has been provided.
$\boxtimes$	Within	n three months of the application filing date or before mailing of a first Office
	Action	on the merits; accordingly, no fee or separate requirements are required.
	Howe	ver, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Action	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue f	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmitta
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 220022001610. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June <u>30</u>, 2004

Respectfully submitted,

Laurie L. Hill, Ph.D.

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7955 Facsimile: (858) 720-5125 Form PTO-1449

0 6 2004

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 220022001610	Application Number 10/806,515
Applicant	
Tom	F. LUE et al.
Filing Date: March 22, 2004	Group Art Unit: 1646
Mailing Date July 1, 2004	

### **U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/1991	5,026,839	Moscatelli et al.	536	27	
	2.	07/1992	5,130,418	Thompson	530	399	
	3.	10/1992	5,155,214	Baird et al.	530	399	
	4.	01/1993	5,180,820	Barde et al.	536	23.51	
	5.	02/1993	5,188,943	Florkiewicz et al.	435	69.4	
	6.	06/1993	5,217,954	Foster et al.	514	12	
	7.	07/1993	5,229,500	Barde et al.	530	399	
	8.	08/1993	5,235,043	Collins et al.	530	399	
	9.	12/1993	5,270,053	Schneider et al.	424	450	
	10.	02/1995	5,387,673	Seddon et al.	530	399	
	11.	08/1995	5,438,121	Barde et al.	530	399	
	12.	09/1996	5,552,157	Yagi et al.	424	450	
	13.	12/1996	5,589,377	Lebkowski	435	369	
-	14.	03/1997	5,607,918	Eriksson et al.	514	012	
-	15.	03/1997	5,646,181	Eriksson et al.	514	012	
	16.	09/1997	5,662,931	Munechika et al.	424	450	
	17.	11/1997	5,686,102	Gross et al.	424	450	
	18.	12/1997	5,693,531	Chiorini et al.	435	325	
	19.	04/1998	5,736,154	Fuisz	424	449	
	20.	04/1998	5,741,511	Lee et al.	424	449	
	21.	05/1998	5,753,500	Shenk et al.	435	320.1	
	22.	11/1998	5,830,725	Nolan et al.	435	455	
	23.	02/1999	5,886,039	Morton	252	301.4R	
	24.	04/1999	5,891,915.	Wysor et al.	514	573	
	25.	08/1999	5,939,096	Clerc et al.	424	450	
	26.	08/1999	5,941,868	Kaplan et al.	604	5000	
	27.	08/1999	5,942,545	Samour et al.	514	573	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

#### Docket Number: 220022001610 Application Number 10/806,515 Form PTO-1449 Applicant INFORMATION DISCLOSURE CITATION Tom F. LUE et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date: March 22, 2004 Group Art Unit:1646 Mailing Date July 1, 2004 08/1999 28. 5,945,117 El-Rashidy et al. 424 430 29. 11/1999 5,981,225 Kochanek et al. 435 069.1 30. 11/1999 5,986,070 Collins et al. 530 404 31. 11/1999 5,994,128 Fallaux et al. 435 325 32. Alving et al. 424 12/1999 6,007,838 450 33. 02/2000 6,031,002 Wysor et al. 514 573 Selim et al. 424 401 34. 05/2000 6,056,966 35. 05/2000 Chamberlain et al. 435 369 6,063,622 06/2000 6,077,829 36. Tanaka et al. 514 021 37. Chamberlain et al. 07/2000 6,083,750 435 369 09/2000 6,120,798 Allen et al. 38. 424 450 39. 10/2000 6,133,026 435 320.1 Huang et al. El-Rashidy et al. 40. 02/2001 6,193,992 424 430 41. 03/2001 6,197,333 Onyuksel et al. 424 450 42. 03/2001 6,197,801 Lin 514 365 Dwarki, et al. 43. 04/2001 6,221,646 B1 435 235.1 44. 06/2001 6,251,871 Jin et al. 514 044 07/2001 6,258,374 Friess et al. 424 430 45. 46. 08/2002 6,436,944 Maytom 514 258 FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Class Subclass Translation Country **Initials** No. YES NO 47. 07/2000 WO00/43029 **WIPO** 48. 04/2001 WO01/24809 **WIPO** 49. 09/2001 **WIPO** WO01/68125 OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc. Examiner Ref. Title **Initials** No. DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number: 220022001610	Application Number 10/806,515		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant  Tom F. LUE et al.			
<del></del>		Filing Date: March 22, 2004	Group Art Unit:1646		
		Mailing Date July 1, 2004			
50.	Achen, et al., Proc. Nat'l. Acad. Sci. U	ISA, 95(2): 548-553 (1998)			
51.	Alm, et al., Acta Physiol. Scand. 148:	421 (1993)	421 (1993)		
52.	Anthony, et al., Placenta, 15: 557 (199	4)			
53.	Asahara, et al., Circulation, 91(11): 27	93-801 (1995)	93-801 (1995)		
54.	Azadzoi, K.M. and I. Saenz de Tejada,	Journal of Urology, 146(1): p. 2	238-40 (1991)		
55.	Baffour, et al., J. Vasc. Surg., 16: 181	(1992)			
56.	Bakircioglu et al., Journal of Urology,	163(4): 198 (2000)			
57.	Banai, et al., Circulation, 89(5): 2183-9	9 (1994)			
58.	Baumgartner, et al., Circulation, 97(12	): 1114-23 (1998)			
59.	Bauters, C., et al., Am. J. Physiol., 267	7(4 Pt 2): H1263-71 (1994)			
60.	Bauters, et al., Circulation, 91(11): 28	02-9 (1995)			
61.	Brown, et al., Lab. Invest., 76: 245 (19	97)			
62.	Burchardt, et al., Biol. Reprod., 60(2):	398 (1999)			
63.	Burchardt, et al., IUBMB Life, 48: 405	5 (1999)			
64.	Carrier, et al., J. Urol., 153: 1722 (199	5)			
65.	Cheung, et al., Am. J. Obstet. Gynecol	., 173: 753 (1995)			
66.	Christ, G. J., Urol Clin North Am, 22:,	727 (1995)			
67.	Claffey, et al., J. Biol. Chem., 267: 163	317 (1992)			
68.	Couper, et al., Circ. Res., 81: 932 (199	7)			
69.	Current Protocols in Molecular Biology, Ausubel, et al. eds., John Wiley & Sons, Inc. (2000), Sambrook, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory press, (1989)				
70.	Current Protocols in Molecular Biology, Ausubel, et al. eds., John Wiley & Sons Press, Chapters 9 and 16 (2000)				
71.	D'Amore, et al., Ann. Rev. Physiol., 49	9(9-10): 453-64 (1987)			
72.	DiStefano, et al., Neuron, 8:983 (1992)				
73.	Dong, J. Y., Fan, P. D. & Frizzell, R. A	., Hum Gene Ther, 7:, 2101 (1996)			
74.	4. During, M. J. and Leone, P., Clin. Neurosci., 3: 292 (1995)				
75.	Dvorak, H.F., et al., Current Topics in Microbiology and Immunology, 237(1): p. 97-132 (1999)				
76.	El-Sakka, et al., J. Urol., 160: 2245 (1	98)			
77.	7. Ferrara, N., Breast Cancer Research and Treatment, 36(2): p. 127-37 (1995)		995)		
EXAMINER:		DATE CONSIDERED:			
	al if citation considered, whether or not the citation to considered. Include a copy of this form with n		ine through the citation if not in		

Form PTO-1449		Docket Number: 220022001610	Application Number 10/806,515	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant  Tom F. LUE et al.		
(Use several sheets if necessary)		Filing Date: March 22, 2004	Group Art Unit:1646	
		Mailing Date July 1, 2004	<u> </u>	
78.	Ferrara, N., et al., Endocr Rev, 13: 18	(1992)		
79.	Folkman, et al., Proc. Nat'l. Acad. Sci.	, 76(10): 5217-21 (1979)		
80.	Folkman, J. and Y. Shing, Journal of E	Biological Chemistry, 267(16): p	. 10931-4 (1992)	
81.	Franck-Lissbrant, I., et al.,. Endocrinol	logy, 139:, 451 (1998)		
82.	Garban, H., Marquez, D., Cai, L. et al.	, Biol Reprod, 53:, 1365 (1995)		
83.	Gimenez y Ribotta, et al., J. Neurosci.	Res., 48: 281 (1997)		
84.	Goldberg, et al., J. Biol. Chem., 269: 4	355 (1994)		
85.	Goldstein, et al., JAMA, 251(7): 903-9	10 (1984)		
86.	Goldstein, International Journal of Imp	ootence Research (2000) 12(4): S	S152-157	
87.	Goodman & Gilman, Pharmacological 77-101	Basis Of Therapeutics, 9th ed.,	McGraw-Hill Press (1996), p.	
88.	Gross, et al., Proc. Nat'l. Acad. Sci., 80	0(9): 2623-27 (1983)		
89.	Grosskreutz, et al., Microvasc. Res., 58	8: 128 (1999)		
90.	Haggstrom, S., Wikstrom, P., Bergh, A	A. et al., Prostate, 36:, 71 (1998)		
91.	Haggstrom, S., Lissbrant, I. F., Bergh, A. et al, J Urol, 161:, 1620 (1999)			
92.	Harada, K., et al., American Journal of	Physiology, 270(5 Pt 2): p. H17	791-802 (1996)	
93.	Hariawala, et al., J. Surg. Res., 63(1):	77-82 (1996)		
94.	Hatzichristou, D. G., Saenz de Tejada,	I., Kupferman, S. et al., J Urol,	153:, 1126 1995	
95.	Heaton, J.P., et al., Int'l J. Impotence F	Res., 8(1): 35-39 (1996)		
96.	Hopkins, et al., J. Vascular Surgery, 27(5): 886-94 (1998)			
97.	Houck, K.A., et al., J. Biol. Chem., 26'	7(36): p. 26031-7 (1992)		
98.	Ide, Neurosci. Res., 25: 101 (1996)			
99.	Jin KL, Mao XO, Greenberg DA., Prod	Natl Acad Sci U S A. 97:1024	2-7 (2000)	
100.	Jingjing, et al., Ophthamol. Vis. Sci., 40: 752 (1999)			
101.	Joukov, et al., EMBO J., 15: 1571 (199	Joukov, et al., EMBO J., 15: 1571 (1996)		
102.	Joukov, et al., EMBO J., 15(2):290-298 (1996)			
103.	Jung, et al., J. Urol., 160: 1899 (1998)			
104.	Jung, et al., Int. J. Impotence Res., 11: 247 (1999)			
105.	Karadeniz, T.,. et al., Urol Int, 55:, 143 (1995)			
106.	Karadeniz, et al., Urol. Int., 57: 85 (1996)			
107.	Kawasuji, et al., Ann. Thorac. Surg., 69: 1155 (2000)			
EXAMINER:		DATE CONSIDERED:		
	al if citation considered, whether or not the citation of considered. Include a copy of this form with n		ine through the citation if not in	

# Docket Number: 220022001610 Application Number 10/806,515 Form PTO-1449 INFORMATION DISCLOSURE CITATION Applicant Tom F. LUE et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date: March 22, 2004 Group Art Unit:1646 Mailing Date July 1, 2004 108. Kim, J.H., et al., Journal of Urology, 151(1): p. 198-205 (1994) 109. Kornowski, et al., Circulation, 101: 545-48 (2000) 110. Korsching, J. Neurosci., 13: 2739 (1993) 111. Laham, et al., J. Am. Coll. Cardiol., 36: 2132-39 (2000) 112. Laham, et al., Curr. Interv. Cardiol. Rep., 1: 228 (1999) 113. Lazarous, et al., J. Am. Coll. Cardiol., 36: 1239 (2000) 114. Lee, et al., J. Urol. 163(4), 198 (2000) 115. Lei, et al., Biochim. Biophys. Acta, 1443: 400 (1998) 116. Leibrock, et al., Nature, 341: 149 (1989) 117. Lekas, E., Johansson, M., Widmark, A. et al., Urol Res, 25:, 309 (1997) 118. Leung, et al., Science, 246: 1306-09 (1989) 119. Levine, F.J., et al., J. Urology, 144(5): 1147-53 (1990) 120. Lewin and Barde, Ann. Rev. Neurosci., 19: 289 (1996) 121. Lin, et al., Proc. Nat'l Acad. Sci. USA, 97: 10242-47 (2000) 122. Liu, et al., J. Urol., 166: 354-360 (2001) 123. Losordo, et al., Am. Heart J., 138(2 Pt 2): 132-41 (1999) 124. Lue, T.F. New Eng. J. Med. 342(24), 1802-1813 (2000) 125. Maeda, Y., Ikeda, U., Ogasawara, Y. et al., Cardiovasc Res, 35:, 514, (1997) 126. Maglione, et al., Oncogene, 8: 925 (1993) 127. Magovern, C.J., et al., Human Gene Therapy, 8(2): p. 215-27 (1997) 128. Mannino and Gould-Fogerite, Bio Techniques, 6:682 (1988) 129. Matsushita, et al., Gene Ther. 5: 938 (1998) 130. McLaughlin, et al., J. Virol. 62: 1963 (1988) 131. Meisel, R. L., O'Hanlon, J. K. & Sachs, B. D., Horm Behav, 18:, 56 (1984) 132. Mersdorf, et al., J. Urol., 154: 749 (1991) 133. Meyer, et al., J. Cell Biol., 119: 45 (1992) 134. Miller, et al., [published erratum appears in Blood 1995 Feb 1;85(3):862]. Blood. 82: 1900 (1993) 135. Mills, T. M., Lewis, R. W. & Stopper, V. S., Biol Reprod, 59: 1413 (1998) 136. Mills, T. M., Stopper, V. S. & Wiedmeier, V. T., Biol Reprod, 51: 234 (1994) 137. Mills, T. M., Dai, Y., Stopper, V. S. et al., 64: 605 (1999) 138. Nehra, et al., J. Urol., 156: 1320 (1996) DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number: 220022001610	Application Number 10/806,515	
INFORMATION DISCLOSURE CITATION		Applicant		
IN AN APPLICATION		Tom F. LUE et al.		
(Use several sheets if necessary)		Filing Date: March 22, 2004	Group Art Unit:1646	
		Mailing Date July 1, 2004		
139. Neu	ifeld, et al., FASEB J., 13(1):9-22 (	1999)		
140. Nor	nomura, et al., Brain Res., 683: 129	(1995)		
141. Oha	ara, et al., Gene Ther., 8: 837 (2001	)		
142. Olo	fsson, et al., Proc. Nat'l. Acad. Sci.	USA, 93: 2576 (1996)		
143. Opp	benheim, et al., Nature, 360: 755 (1	992)		
144. Orte	ega, et al., Front. Biosci. 4(4):D141	-152 (1999)		
145. Paid	ck et al., Urology, 42: 145 (1993)			
146. Parl	k et al., Int'l J. Impotence Res., 9(1	1): 27-37 (1997)		
147. Parl	ker, et al., Steroid Biochem, 6:, 1, (	1975)		
148. Pod	lsakoff, et al., J. Virol. 68: 5656, (19	994)		
149. Pol	torak, et al., J. Biol. Chem., 272(11)	): 7151-78 (1997)		
150. Pue	yo, et al., Exp. Cell Res., 238: 354	(1998)		
151. Qua	antin, et al., Proc. Natl. Acad. Sci. U	JSA, 89:2581-2584 (1992)		
152. Raj	anayagam, et al., J. Am. Coll. Card	iol., 35: 519 (2000)		
153. Rak	cue, et al., Japan Circ. J., 62: 933-39	9 (1998)		
154. Ros	Rosen, M.P., et al., Radiology, 174(3 Pt 2): 1043-48 (1990)			
155. Ros	Rosenfeld, et al., Cell, 68:143-155 (1992)			
156. Shv	veiki, et al., Proc. Nat'l Acad. Sci. I	JSA, 92: 768 (1995)		
157. Son	dell, et al., Eur. J. Neurosci., 12: 42	243-54 (2000)		
158. Ster	nberg, P. E., Shuman, M. A., Levin	e, S. P. et al., J Cell Biol, 98: 74	8 (1984)	
159. Stra	atford-Perricadet, et al., J. Clin. Inve	est., 90:626-630 (1992)		
160. Syn	nes, et al., Ann. Thorac. Surg., 68:	330 (1999)		
161. Tak				
162. Tak	eshita, et al., J. Clin. Invest., 93(2):	662-70 (1994)		
163. Tak	Takeshita, et al., Circulation, 90(5 Pt 2): II228-34 (1994)			
164. Tisc				
165. Ung	Unger, et al., Am. J. Cardiol., 85: 1414-19 (2000)			
166. Ver	Verdonck, A., De Ridder, L., Arch Oral Biol, 43:, 551 (1998)			
167. Wal				
168. Wal				
169. Waltenberger, et al., J. Biol. Chem., 269: 26988 (1994)				
EXAMINER:		DATE CONSIDERED:		
	tation considered, whether or not the citatic sidered. Include a copy of this form with no		ine through the citation if not in	

				Sheet 7 of 7	
Form PTO-1449			Docket Number: 220022001610	Application Number 10/806,515	
INFOR	MATI	ON DISCLOSURE CITATION	Applicant		
IN AN APPLICATION			Tom F. LUE et al.		
	(Us	se several sheets if necessary)	several sheets if necessary) Filing Date: March 22, 2004 Group Art Unit: 1646		
			Mailing Date July 1, 2004		
	170.	Watson et al. Molecular Biology of the Gene, 4th Edition, The Bejacmin/Cummings Pub. co., p. 224 (1987)			
	171.	Yamada, et al., Genomics, 42: 483 (1997)			
	172.	Yan, et al., Nature, 360: 753 (1992)			
	173.	Zheng, et al., Am. J. Physiol. Heart Circ. Physiol., 280: H909-17 (2001)			
	174.	Zvara, P., Sioufi, R., Schipper, H. M. et al., Int J Impot Res, 7: 209 (1995)			

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.